News
Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know - Nasdaq
Novo Nordisk's share price fell as well on Monday. However, the big pharma stock tumbled only around 5%, reflecting a much more muted impact on its business from scrapping the deal with Hims & Hers.
Novo Nordisk confirmed on Monday it would cease its agreement with U.S. telehealth firm Hims & Hers Health regarding its Wegovy weight-loss drug, prompting a 31% dip in Hims shares during morning ...
When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk’s NovoCare Pharmacy for a discounted price of $499 per ...
Novo Nordisk has ended its partnership with Hims & Hers, citing concerns over the telehealth company’s promotion and sale of the drugmaker’s compounded versions of Wegovy. The drugmaker ...
Spain’s ministry of health has asked Novo Nordisk for clarification about a controversial obesity awareness campaign which may have broken the country’s law on promoting prescription drugs. The ...
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes.
Health Care Declines as Hims, Novo Nordisk Slide on Deal Breakup - Health Care Roundup - MarketWatch
Health-care companies fell as a major alliance in the obesity drug market crumbled. Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk ...
Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the digital pharmacy, citing "illegal" and "deceptive" practices.
Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both jumped 0 ...
Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results